Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TARO-AMCINONIDE 0.1 % — DIN 02246714

AMCINONIDE : 0.1 % · TARO PHARMACEUTICALS INC · CREAM · wholesale supply in Canada

Health Canada status: MARKETED

What is TARO-AMCINONIDE?

TARO-AMCINONIDE 0.1 % contains AMCINONIDE : 0.1 %. It is listed in the Health Canada Drug Product Database under DIN 02246714, held by TARO PHARMACEUTICALS INC, supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 24-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is TARO-AMCINONIDE used for?

TARO-AMCINONIDE (amcinonide) is a high potency topical corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses for a maximum duration of 5 days on the face, axillae, scrotum and scalp and a maximum of 3 weeks on the body.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Is there a generic Amcinonide in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

4 holders have a Canadian DIN containing Amcinonide, across 11 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
TARO PHARMACEUTICALS INC21TARO-AMCINONIDESourceable in Canada
GLAXOSMITHKLINE INC30CYCLOCORTNo marketed DIN
LEDERLE CYANAMID CANADA INC.30CYCLOCORT CRM 0.1%, CYCLOCORT LOT 0.1%, CYCLOCORT ONT 0.1%No marketed DIN
TEVA CANADA LIMITED30RATIO-AMCINONIDENo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label0.1 %
Dosage formCREAM
RouteTOPICAL
Pack configuration (monograph)TARO-AMCINONIDE ointment is available in 15, 30, and 60 grams laminate tubes. TARO-AMCINONIDE cream is available in 15, 30, and 60 grams laminate tubes, and in 100 grams polypropylene jars.
Storagecontrolled room temperature 15°-30°C. Keep the container tightly closed. Avoid freezing.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.

Substance and classification

Active substanceAmcinonide
ATC codeD07AC11
AHFS class84:06.00
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02246714
DIN (unpadded, as printed on some documents)2246714
Brand nameTARO-AMCINONIDE
Generic / active ingredientAMCINONIDE : 0.1 %
Market authorization holderTARO PHARMACEUTICALS INC
Health Canada schedulePrescription
ATC codeD07AC11
ATC anatomical main groupD — Dermatologicals
ATC therapeutic subgroupD07AC
Current statusMARKETED
Status date24-Oct-2005
Original market date2003-02-13 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

1 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
CYCLOCORT0.1 %OINTMENTGLAXOSMITHKLINE INCCANCELLED POST MARKET02192268
CYCLOCORT0.1 %CREAMGLAXOSMITHKLINE INCCANCELLED POST MARKET02192284
CYCLOCORT0.1 %LOTIONGLAXOSMITHKLINE INCCANCELLED POST MARKET02192276
CYCLOCORT CRM 0.1%.1 %CREAMLEDERLE CYANAMID CANADA INC.CANCELLED POST MARKET00443824
CYCLOCORT LOT 0.1%.1 %LOTIONLEDERLE CYANAMID CANADA INC.CANCELLED POST MARKET00571016
CYCLOCORT ONT 0.1%.1 %OINTMENTLEDERLE CYANAMID CANADA INC.CANCELLED POST MARKET00559237
RATIO-AMCINONIDE0.1 %OINTMENTTEVA CANADA LIMITEDCANCELLED POST MARKET02247096
RATIO-AMCINONIDE0.1 %LOTIONTEVA CANADA LIMITEDCANCELLED POST MARKET02247097
RATIO-AMCINONIDE0.1 %CREAMTEVA CANADA LIMITEDCANCELLED POST MARKET02247098
TARO-AMCINONIDE0.1 %OINTMENTTARO PHARMACEUTICALS INCCANCELLED PRE MARKET02257416

2 · Same class — other molecules in ATC D07AC

MoleculeCanadian brandsDINsMarketedSourceable
BetamethasoneBEBEN GEL 0.025% · BETACORT SCALP LOTION 0.1% · BETADERM CRM 0.05% · BETADERM CRM 0.1% · +55 more7320Yes
MometasoneELOCOM · PMS-MOMETASONE · TARO-MOMETASONE CREAM · TARO-MOMETASONE LOTION · +2 more116Yes
FluocinonideLIDEMOL · LIDEMOL 0.05% · LIDEX · LIDEX CREAM MILD 0.01% · +10 more184Yes
DesoximetasoneDESOXI CREAM 0.05% · DESOXI CREAM 0.25% · DESOXI GEL 0.05% · TOPICORT · +6 more144Yes
UlobetasolBRYHALI · ULTRAVATE33Yes
Fluocinolone AcetonideCAPEX · DERMA SMOOTHE/FS LIQ 0.01% · FLUODERM CRM 0.01% · FLUODERM CRM 0.025% · +10 more151Yes
AmcinonideCYCLOCORT · CYCLOCORT CRM 0.1% · CYCLOCORT LOT 0.1% · CYCLOCORT ONT 0.1% · +2 more111Yes
BeclometasonePROPADERM · PROPADERM CREAM 0.025% · PROPADERM LOT 0.025% · PROPADERM LOTION 0.025%41Yes
PrednicarbateDERMATOP EMOLLIENT CREAM · DERMATOP OINTMENT21Yes
DiflucortoloneNERISONE CREAM · NERISONE OILY CREAM · NERISONE OINTMENT30Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC D07A

ATC subgroupMoleculesDINsMarketed
D07ADClobetasol · Halcinonide4320
D07ABClobetasone · Desonide · Flumetasone · Triamcinolone327
D07AAHydrocortisone · Methylprednisolone353

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for TARO-AMCINONIDE

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02246714. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.